Our Solution
The Market Opportunity
Over 200 million dogs & 200 million cats living in Europe and US, have guardians increasingly see them as family.
Number of pets insured have increased more than 3-fold in the last 7 years.
The global veterinary medicine market was estimated at $50 billion in 2024 and is expected to grow to $80 billion by 2030.
Our First Breakthrough Therapy
Nebumet is an off-the-shelf nebulized immunotherapy that treats and prevents lung metastases in dogs with solid tumors. Our proprietary formulation of the proven BCG vaccine is delivered directly to the lungs where cancer often spreads, extending survival while maintaining quality of life. With multiple patent protections through 2045 and a clear regulatory pathway, Nebumet offers a compelling investment opportunity.
Novel delivery of established immunotherapy with >30 years of human safety data
Shown great potential already in improvement of survival time in dogs
First veterinary market approval expected 2028
The Scientific Foundation
Our comparative oncology approach recognizes that canine cancers mirror human disease, offering valuable insights for treatments across species. Nebumet works by triggering local immune activation in the lungs to combat metastatic cancer cells, addressing a critical weakness in current treatment protocols. Our technology is backed by safety and efficacy evidence across multiple species and targets the most lethal aspect of cancer—metastasis.
Robust in vivo evidence across multiple species supports efficacy
Mechanism activates the body's immune system against cancer cells
Platform technology expandable to multiple cancer types and species
